| Q37308467 | A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. |
| Q52582240 | A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. |
| Q53111697 | Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. |
| Q39198649 | Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. |
| Q38317235 | Chemotherapy-free treatment in patients with follicular lymphoma |
| Q38111389 | Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma |
| Q38171874 | Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges |
| Q48287153 | Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL). |
| Q36724776 | Considerations in the initial management of follicular lymphoma |
| Q38056393 | Current and future management of follicular lymphoma. |
| Q48185856 | Current prognostic and predictive factors in follicular lymphoma |
| Q38187365 | Current role of FDG PET/CT in lymphoma |
| Q40765432 | Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). |
| Q41481956 | Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. |
| Q36429831 | Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement. |
| Q90916353 | Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply |
| Q43792807 | Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. |
| Q99561773 | Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models |
| Q35080079 | FDG PET-CT in follicular lymphoma: a case-based evidence review |
| Q91414532 | FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma |
| Q38312367 | FDG PET/CT imaging as a biomarker in lymphoma. |
| Q53135049 | FDG PET/CT predictive role in follicular lymphoma. |
| Q33642244 | FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management |
| Q37632114 | FDG-PET imaging in hematological malignancies |
| Q41840128 | FDG-PET in Follicular Lymphoma Management |
| Q52982144 | FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. |
| Q39386942 | Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. |
| Q88801099 | Follicular Lymphoma: Past, Present, and Future |
| Q92185611 | Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs |
| Q38191811 | How we manage follicular lymphoma |
| Q41008736 | Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. |
| Q38345572 | Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. |
| Q34223214 | Impact of (18)F-FDG PET/CT on the staging and management of follicular lymphoma |
| Q39727079 | Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up |
| Q37193816 | Incorporating prognostic imaging biomarkers into clinical practice |
| Q36967098 | Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party |
| Q37577874 | Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era? |
| Q33407093 | Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer |
| Q33558757 | Nature and importance of follicular lymphoma precursors |
| Q59273877 | Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q61797216 | Novel treatment approaches and future perspectives in follicular lymphoma |
| Q26752284 | PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas |
| Q38794783 | PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma |
| Q89090599 | PET-CT restaging: a surrogate for follicular lymphoma? |
| Q38179303 | PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study |
| Q53083933 | PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. |
| Q38142869 | PET/CT in malignant lymphoma: basic information, clinical application, and proposal |
| Q53058794 | Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography. |
| Q36399538 | Positron emission tomographic scans in lymphoma: convention and controversy |
| Q90638540 | Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma |
| Q53124984 | Prognostic assessment in patients with indolent B-cell lymphomas. |
| Q38794103 | Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies |
| Q57481825 | Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial |
| Q27027445 | Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review |
| Q49894028 | Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation |
| Q34663865 | Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification |
| Q42603371 | Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. |
| Q38417140 | Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma |
| Q37240835 | Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. |
| Q44908024 | SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma |
| Q37144956 | State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". |
| Q28073262 | Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How |
| Q28072397 | The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era |
| Q42033589 | The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis |
| Q44592953 | The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). |
| Q53060303 | The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. |
| Q53140301 | The role of FDG-PET and bone marrow examination in lymphoma staging. |
| Q46638000 | The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. |
| Q38110318 | The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma |
| Q93018892 | Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a stu |
| Q41730322 | Three-dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: comparison with F-18-FDG PET. |
| Q48129191 | To maintain or not, that is the question |
| Q50710717 | Unmet needs in the first-line treatment of follicular lymphoma. |
| Q45327264 | Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy |
| Q38153086 | When should FDG-PET be used in the modern management of lymphoma? |
| Q46450889 | [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice |